GE HealthCare Study: Adding PET/CT Scan With [18F]FES Breast Oncology Tracer To Standard Workup May Improve ER Status Accuracy, Save $142M Over Five Years In US
Portfolio Pulse from Benzinga Newsdesk
A GE HealthCare study suggests that incorporating PET/CT scans with the [18F]FES breast oncology tracer into the standard workup for breast cancer patients could improve the accuracy of estrogen receptor (ER) status determination and potentially save $142 million over five years in the US.
June 04, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GE HealthCare's study indicates that using PET/CT scans with [18F]FES tracer in breast cancer diagnostics could enhance ER status accuracy and save $142 million over five years in the US.
The study highlights a significant improvement in diagnostic accuracy and cost savings, which could lead to increased adoption of GE HealthCare's PET/CT technology and [18F]FES tracer, potentially boosting revenues and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100